Aerosol delivery systems for bronchial asthma

Postgraduate Medical Journal

Volumn 72, Issue 845, 1996, Pages 151-156

  Ariyananda, P L ^a   Agnew, J E ^a   Clarke, S W ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Aerosols; Asthma; Inhalation devices; Nebulisers

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CROMOGLYCATE DISODIUM; FENOTEROL; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; SALBUTAMOL; STEROID; TERBUTALINE SULFATE;

AEROSOL; ASTHMA; DRUG TARGETING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; NEBULIZER; REVIEW;

EID: 0029988405     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.72.845.151     Document Type: Review

References (28)

1. Newman SP, Clarke SW. Inhalation devices and techniques. In: Clark TJH, Godfrey S, Lee TH, eds. Asthma. London: Chapman and Hall, 1992; pp 469-505.
2. Freedman T. Medihaler therapy for bronchial asthma: a new type of aerosol therapy. Postgrad Med J 1956; 20: 667-73.
3. Barnes PJ. Neural mechanisms in asthma. Br Med Bull 1992; 48: 149-68.
4. New-man SP, Clark AR, Talaee N, Clarke SW. Pressurised aerosol deposition in the human lung with and without an 'open' spacer device. Thorax 1989; 44: 706-10.
5. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur Respir J 1989; 2: 247-52.
6. Nebulisers. British National Formulary 1994; 27: 119-21.
7. Newman SP. Production of radioaerosols. In: Clarke SW, Pavia D, eds. Aerosols and the lung. London: Butterworths, 1984; pp 71-91.
8. Stuart BO. Deposition of inhaled aerosols. Arch Intern Med 1973; 131: 60-3.
9. Hashish AH. Selective deposition of pulsed aerosols in the human lung. J Aerosol Sci 1992; 23 (suppl 1): 473-6.
10. Porstendorfer J, Gebhart J, Robig G. Effect of evaporation on the size distribution of nebulized aerosols. J Aerosol Sci 1977; 8: 371.
11. Hayton WL. Propellent-powered nebulizers. J Am Pharm Assoc 1976; 16: 201.
12. Dolovich MB, Ruffin RE, Roberts R, Newhouse MT. Optimal delivery of aerosols from metered dose inhalers. Chest 1981; 80 (suppl): 911.
13. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive aerosols. Eur J Respir Dis 1982; 63 (suppl): 57-65.
14. Newhouse MT, Ruffin R. Deposition and fate of aerosolized drugs. Chest 1978; 73: 936-43.
15. Pavia D, Thomson ML, Shannon HS. The effect of airway obstruction and tidal volume of aerosol inhaled on the depth of deposition in the human lung. Arch Environ Health 1977; 32: 131-7.
16. Cushley MJ, Holgate ST. Efficacy of inhaled methylxanthines as bronchodilators in asthma. Thorax 1983; 38: 223.
17. Melchor R, Biddiscombe MF, Mack VH, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506-11.
18. Salmeterol xinafoate. In: Reynolds, JEF, ed Martindale. The extra phamacopoeia. 1993; London: The Pharmaceutical Press, 1993; p 1257.
19. Crane J, Pearce NE, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case controlled study. Lancet 1989; i: 917-22.
20. Pearce N, Beasely R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995; 345: 41-4.
21. Burgess C, Pearce N, Thiruchelvam R, et al. Prescribed drug therapy and near fatal asthma attacks. Eur Respir J 1994; 7: 498-503.
22. Blauw GJ, Westendorp J. Asthma deaths in New Zealand: whodunnit? (commentary) Lancet 1995; 345: 2-3.
23. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 (suppl A): 25-9.
24. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. Comparison of fluticasone propionate 1 mg daily with beclomethasone dipropionate 2 mg daily in the treatment of severe asthma. Eur Respir J 1993; 6: 877-84.
25. Ayres JG, Harris TAJ, Bateman ED, Lundback B. The effects of fluticasone propionate 1 mg and 2 mg daily, and budesonide 1.6 mg daily in severe asthmatics. Thorax 1994; 49: 403.
26. Newman SP. Therapeutic aerosols. In: Clarke SW, Pavia D, eds. Aerosols and the lung. London: Butterworths, 1984; pp 197-224.
27. Riley DJ, Liu RT, Edelman NH. Enhanced responses to aerosolized bronchodilator therapy in asthma using respiratory manoeuvres. Chest 1979; 76: 501-7.
28. Lawford P, McKenzie D. Pressurised aerosol inhaler technique: how important are the inhalations from residual volume, inspiratory flow rate and time interval between puffs? Br J Dis Chest 1983; 77: 276-81.